Richard Clark
Dieser Inhalt ist noch nicht in deiner Sprache verfügbar.
Richard Clark is a plastic surgeon whose published work on botulinum toxin for facial asymmetry is part of the early cosmetic-use pathway before Botox Cosmetic became a formal U.S. aesthetic label. His relevance is narrow and historical: early aesthetic-adjacent publication, not broad modern brand leadership.
Clark’s role should be read alongside, not instead of, Jean Carruthers and Alastair Carruthers. The Carruthers pages remain the main glabellar-line adoption pathway for Botox Cosmetic, while Clark preserves the earlier published facial-asymmetry and forehead-wrinkle context.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Professional field | Plastic surgery |
| Historical relevance | Early published aesthetic-adjacent botulinum toxin use |
| Relevant brand | Botox / Botox Cosmetic |
| Related people | Jean Carruthers and Alastair Carruthers |
| Main historical distinction | Facial asymmetry and forehead-wrinkle context before the 2002 U.S. Botox Cosmetic glabellar-line approval |
Career Notes
Section titled “Career Notes”- Clark’s 1989 publication with Berris described botulinum toxin use for facial asymmetry caused by facial nerve paralysis.
- The case is often discussed in histories of aesthetic botulinum toxin because it involved forehead muscle activity and appearance-related asymmetry.
- The Carruthers’ later glabellar-line work became the central clinical and commercial pathway behind Botox Cosmetic’s aesthetic-market identity.
- Botox Cosmetic received U.S. approval for glabellar lines in 2002, well after these early publications and observations.
Why Richard Clark Matters
Section titled “Why Richard Clark Matters”Clark matters because cosmetic botulinum toxin history is easy to flatten into a single discovery story. His role preserves a more precise sequence: early appearance-related case publication, Carruthers glabellar-line work, then formal product-label and commercial expansion.
That sequence improves accuracy without turning a historical case report into a modern claim. It does not imply that later products share Botox’s labels, dose scale, indications, or safety profile.
Activity and Public Context
Section titled “Activity and Public Context”Clark is most relevant to Botox Cosmetic history and aesthetic-use origin discussions. He is not a current product, company, or regulatory reference. Product claims should still be anchored to current prescribing information and local approvals.